What is the share price of Sandu Pharmaceuticals Ltd (SANDUPHQ) today?
The share price of SANDUPHQ as on 11th March 2025 is ₹49. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Sandu Pharmaceuticals Ltd (SANDUPHQ) share?
The past returns of Sandu Pharmaceuticals Ltd (SANDUPHQ) share are- Past 1 week: 14.47%
- Past 1 month: 2.48%
- Past 3 months: -6.52%
- Past 6 months: -19.68%
- Past 1 year: -13.47%
- Past 3 years: -13.08%
- Past 5 years: 254.85%
What are the peers or stocks similar to Sandu Pharmaceuticals Ltd (SANDUPHQ)?
The peers or stocks similar to Sandu Pharmaceuticals Ltd (SANDUPHQ) include:What is the dividend yield % of Sandu Pharmaceuticals Ltd (SANDUPHQ) share?
The current dividend yield of Sandu Pharmaceuticals Ltd (SANDUPHQ) is 1.49.What is the market cap of Sandu Pharmaceuticals Ltd (SANDUPHQ) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sandu Pharmaceuticals Ltd (SANDUPHQ) is ₹51.94 Cr as of 11th March 2025.What is the 52 week high and low of Sandu Pharmaceuticals Ltd (SANDUPHQ) share?
The 52-week high of Sandu Pharmaceuticals Ltd (SANDUPHQ) is ₹69.50 and the 52-week low is ₹47.What is the PE and PB ratio of Sandu Pharmaceuticals Ltd (SANDUPHQ) stock?
The P/E (price-to-earnings) ratio of Sandu Pharmaceuticals Ltd (SANDUPHQ) is 35.33. The P/B (price-to-book) ratio is 1.28.Which sector does Sandu Pharmaceuticals Ltd (SANDUPHQ) belong to?
Sandu Pharmaceuticals Ltd (SANDUPHQ) belongs to the Consumer Staples sector & FMCG - Personal Products sub-sector.How to buy Sandu Pharmaceuticals Ltd (SANDUPHQ) shares?
You can directly buy Sandu Pharmaceuticals Ltd (SANDUPHQ) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Sandu Pharmaceuticals Ltd
SANDUPHQSandu Pharmaceuticals Ltd
SANDUPHQ
Consumer StaplesFMCG - Personal Products
SmallcapWith a market cap of ₹51 cr, stock is ranked 3,450
Moderate RiskStock is 2.61x as volatile as Nifty
49.008.85% (-4.76)
49.008.85% (-4.76)
Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 35.33 | 1.28 | 1.49% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 45.92 | 8.99 | 1.61% |
Forecast & Ratings
Detailed Forecast —
Forecast data is currently unavailable for this stockPrice
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Sandu Pharmaceuticals is engaged in manufacturing and marketing of ayurvedic medicine
Peers
Compare with peersGODREJCP
PE Ratio
-190.53
1Y Return
15.69%
Buy Reco %
73.53
DABUR
PE Ratio
47.45
1Y Return
7.51%
Buy Reco %
55.00
MARICO
PE Ratio
53.08
1Y Return
19.27%
Buy Reco %
82.86
PE Ratio
50.15
1Y Return
6.38%
Buy Reco %
38.10
PE Ratio
64.42
1Y Return
16.22%
Buy Reco %
50.00
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Annual Normal View
Income Statement
Annual Normal View
| Financial Year | FY 2022 | FY 2023 | FY 2024 | TTM | ||||
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 65.58 | 65.68 | 67.70 | 68.19 | ||||
Raw Materials | 62.63 | 34.27 | 30.94 | 65.34 | ||||
| Power & Fuel Cost | 0.39 | 0.41 | ||||||
| Employee Cost | 11.10 | 10.07 | ||||||
| Selling & Administrative Expenses | 13.75 | 15.24 | ||||||
| Operating & Other expenses | 3.35 | 8.32 | ||||||
EBITDA | 2.95 | 2.82 | 2.72 | 2.85 | ||||
| Depreciation/Amortization | 0.53 | 0.52 | 0.58 | 0.66 | ||||
| PBIT | 2.42 | 2.30 | 2.14 | 2.19 | ||||
| Interest & Other Items | 0.11 | 0.08 | 0.06 | 0.08 | ||||
| PBT | 2.31 | 2.22 | 2.08 | 2.11 | ||||
| Taxes & Other Items | 0.73 | 0.69 | 0.61 | 0.64 | ||||
| Net Income | 1.58 | 1.53 | 1.47 | 1.47 | ||||
| EPS | 1.99 | 1.58 | 1.52 | 1.52 | ||||
| DPS | — | 0.00 | 0.80 | 0.80 | ||||
| Payout ratio | 0.00 | 0.00 | 0.53 | 0.53 |
Company Updates
FY 2015
Annual report
PDFFY 2016
Annual report
PDFFY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2022
Annual report
PDFFY 2023
Annual report
PDFFY 2024
Annual report
PDFPeers & Comparison
Comparing 3 stocks from
Consumer StaplesFMCG - Personal Products
Compare valuation on Screener
Consumer StaplesFMCG - Personal Products
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Sandu Pharmaceuticals Ltd | 35.33 | 1.28 | 1.49% |
| Godrej Consumer Products Ltd | -190.53 | 8.48 | 1.44% |
| Dabur India Ltd | 47.45 | 8.49 | 1.11% |
| Marico Ltd | 53.08 | 18.86 | 1.56% |
Price Comparison
Compare SANDUPHQ with any stock or ETFCompare SANDUPHQ with any stock or ETF
SANDUPHQ
Shareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 19, 2024
Final
Final | Div/Share: ₹0.80
Dividend/Share
₹0.80
Ex DateEx Date
Sep 19, 2024
Cash Dividend
Ex DateEx DateSep 18, 2023
Final
Final | Div/Share: ₹0.75
Dividend/Share
₹0.75
Ex DateEx Date
Sep 18, 2023
Cash Dividend
Ex DateEx DateSep 23, 2022
Final
Final | Div/Share: ₹0.75
Dividend/Share
₹0.75
Ex DateEx Date
Sep 23, 2022
Cash Dividend
Ex DateEx DateSep 22, 2021
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Sep 22, 2021
News & Opinions
Articles & Videos
Earnings
Sandu Pharmaceuticals standalone net profit rises 166.67% in the December 2024 quarter
Net profit of Sandu Pharmaceuticals rose 166.67% to Rs 0.56 crore in the quarter ended December 2024 as against Rs 0.21 crore during the previous quarter ended December 2023. Sales rose 5.39% to Rs 18.37 crore in the quarter ended December 2024 as against Rs 17.43 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales18.3717.43 5 OPM %5.442.93 - PBDT0.990.52 90 PBT0.800.38 111 NP0.560.21 167 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Sandu Pharmaceuticals to convene board meeting
Sandu Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 February 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Sandu Pharmaceuticals consolidated net profit declines 9.09% in the September 2024 quarter
Net profit of Sandu Pharmaceuticals declined 9.09% to Rs 0.50 crore in the quarter ended September 2024 as against Rs 0.55 crore during the previous quarter ended September 2023. Sales rose 6.56% to Rs 17.70 crore in the quarter ended September 2024 as against Rs 16.61 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales17.7016.61 7 OPM %5.144.94 - PBDT0.910.90 1 PBT0.740.76 -3 NP0.500.55 -9 Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Sandu Pharmaceuticals standalone net profit declines 9.09% in the September 2024 quarter
Net profit of Sandu Pharmaceuticals declined 9.09% to Rs 0.50 crore in the quarter ended September 2024 as against Rs 0.55 crore during the previous quarter ended September 2023. Sales rose 6.56% to Rs 17.70 crore in the quarter ended September 2024 as against Rs 16.61 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales17.7016.61 7 OPM %5.144.88 - PBDT0.910.89 2 PBT0.740.76 -3 NP0.500.55 -9 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Sandu Pharmaceuticals declare Quarterly Result
Sandu Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Sandu Pharmaceuticals AGM scheduled
Sandu Pharmaceuticals announced that the 39th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Board of Sandu Pharmaceuticals recommends final dividend
Sandu Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 12 August 2024, inter alia, have recommended the final dividend of Rs 0.8 per equity Share (i.e. 8%) , subject to the approval of the shareholders.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Sandu Pharmaceuticals consolidated net profit rises 54.55% in the June 2024 quarter
Net profit of Sandu Pharmaceuticals rose 54.55% to Rs 0.17 crore in the quarter ended June 2024 as against Rs 0.11 crore during the previous quarter ended June 2023. Sales declined 3.45% to Rs 17.05 crore in the quarter ended June 2024 as against Rs 17.66 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales17.0517.66 -3 OPM %2.402.04 - PBDT0.430.33 30 PBT0.270.21 29 NP0.170.11 55 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Sandu Pharmaceuticals schedules board meeting
Sandu Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 August 2024.Powered by Capital Market - Live
7 months agoCapital Market - Live
Why are shares of JP Associates, Va Tech Wabag, JP Power, Rail Vikas Nigam and Sandu Pharma, rallying today?
2 years agoBusiness Today
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant